The bright side of psychoactive substances: cannabinoid-based drugs in motor diseases

R. Coccurello & T. Bisogno

To cite this article: R. Coccurello & T. Bisogno (2016): The bright side of psychoactive substances: cannabinoid-based drugs in motor diseases, Expert Review of Clinical Pharmacology, DOI: 10.1080/17512433.2016.1209111

To link to this article: http://dx.doi.org/10.1080/17512433.2016.1209111
The bright side of psychoactive substances: cannabinoid-based drugs in motor diseases

R. Coccurello¹²*, T. Bisogno³⁴*

¹Institute of Cell Biology and Neurobiology (IBCN) National Research Council (C.N.R.), Via del Fosso di Fiorano 64 - 00143 Roma, Italy.
²Fondazione S. Lucia (FSL- IRCCS), Via del Fosso di Fiorano 64 - 00143 Roma, Italy.
³Endocannabinoid Research Group, Institute of Biomolecular Chemistry, National Research Council (C.N.R.), Via C. Flegrei 34 - 80078 Pozzuoli, Italy.
⁴Department of Medicine, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 21 - 00128, Roma, Italy.

*Corresponding authors:
T.B., Endocannabinoid Research Group, Institute of Biomolecular Chemistry, National Research Council (C.N.R.), Via C. Flegrei 34, 80078 Pozzuoli, Italy;
Tel.: +39081 8675093; +39-06 225419106
E-mail: tbisogno@icb.cnr.it
R.C., Institute of Cell Biology and Neurobiology (IBCN) National Research Council (C.N.R.)/IRCCS Fondazione S. Lucia (FSL), Via del Fosso di Fiorano 64 – 00143 Roma, Italy.
Tel.: +3906 501703279;
E-mail: roberto.coccurello@cnr.it

Abstract
Introduction: psychoactive substances are associated with the idea of drugs with high addictive liability, affecting mental states, cognition, emotion and motor behavior. However these substances can modify synaptic transmission and help to disclose some mechanisms underlying alterations in brain processing and pathophysiology of motor disease. Hence, the “bright side” of cannabinoid-based drugs must be thoroughly examined to be identified within the latter framework.

Areas covered: we will analyze the preclinical and clinical evidence of cannabinoid-based drugs, discussing their therapeutic value in basal ganglia motor disorders such as Parkinson’s disease and Huntington disease.

Expert commentary: despite the knowledge acquired in the last years, the therapeutic potential of cannabinoid-based drugs should be further tested by novel routes of investigation. This should be focused on the role of cannabinoid signaling system in mitochondrial function as well as on the physical and functional interaction with other key receptorial targets belonging to this network.

Key words: Parkinson’s disease; Huntington disease; endocannabinoid system; motor diseases; cannabinoid-based drugs; neuroprotection.

1. Cannabinoids and the “tune up” of brain locomotor circuits

The major and measurable impact of psychoactive substances (PS) is on motor function, and the extent to which PS affect, alter or modulate psychomotricity and locomotor patterns can be assumed as index of their whole action on central nervous system functioning. Indeed, a non-exhaustive list of PS should include at least ethanol, nicotine, hypnotics and sedatives, opioids, dopamine-active compounds and cannabinoids. All these PS have a dramatic impact on motor function producing sedation and motor incoordination (ethanol, hypnotics and sedatives, opioids), arousal, sensitization and locomotor-enhancing effects (nicotine), hyperlocomotion and motor sensitization (cocaine, amphetamines) and dose- and context-dependent opposite effects on motor activity (cannabinoids).

Thus, quite a few of these PS are considered of key importance for their action in the control of motor function and consequently for the therapeutic potential in specific pathophysiologic conditions. Here, we discuss some motor dysfunctions and disorders in which endocannabinoids (eCBs), synthetic and plant derivative cannabinoids modulate motor symptoms and can be
explored as therapeutic option for the treatment of movement disorders. However, given the broad definition of movement disorders we will focus on one selected hypokinetic disorder such as Parkinson’s disease (PD) and one hyperkinetic and akinetic-rigid (in advanced stage) disorder such as Huntington’s disease (HD). It is worth mention that focusing on PD and HD does not imply that cannabinoids are not involved in other extrapyramidal disorders such as Gilles de la Tourette’s syndrome (TS), tardive dyskinesia and dystonia and would not be of interest to assess the effects of cannabinoid-based drugs in these disorders. Nevertheless, one may ask why cannabinoid-based drugs should be favored candidates for therapeutic intervention over other PS targeting for instance the cholinergic receptors. The legitimate question calls into play their special role in synaptic plasticity and balance of the basal ganglia (BG) output and their interaction with the major BG neurotransmitter systems (glutamatergic, dopamine-(DA)ergic, GABAergic and cholinergic) to select appropriate motor responses. The identification and cloning, in the brain and in immune organs of cannabinoid receptor type-1 (CB$_1$) and type-2 (CB$_2$), respectively, have opened new opportunities to understand how Δ$_9$-tetrahydrocannabinol (THC), the main psychoactive component of *Cannabis sativa*, and its synthetic analogs, act to produce their pharmacological responses [1]. Both CB$_1$ and CB$_2$ receptors are seven-transmembrane domain proteins coupled to G-proteins type Gi/o and, less frequently, to the Gs type [2]. The existence of these two receptors entailed the presence of endogenous ligands or eCBs, i.e. *N*-arachidonoyl-ethanolamine (anandamide, AEA) and 2-arachidonoyl-glycerol (2-AG) that activate these receptors, were identified in mammals [1]. These molecules are biosynthesized (Figure 1) via the processing of membrane lipid precursors, i.e. *N*-arachidonoyl-phosphatidylethanolamine (N-ArPE) and sn-2-arachidonate containing diacylglycerols (DAG), by the action of *N*-acyl-phosphatidylethanolamine-selective phospholipase D (NAPE-PLD) and diacylglycerol lipases (DAGL) $\alpha$ and $\beta$, in AEA and 2-AG, respectively. eCBs are then inactivated by intracellular hydrolyzing enzymes, i.e. fatty acid amide hydrolase (FAAH) and the monoacylglycerol lipase (MAGL), respectively [3,4]. Receptors, eCBs and the proteins responsible for their metabolism are the key components of the complex endogenous signaling network known as the eCB system. Recent comprehensive reviews highlighted as complexity and redundancy of eCB molecular targets and metabolic pathways required a full revision of this definition [5-7]. Briefly, eCBs as well as some plant derived cannabinoids, phytocannabinoids, bind to molecular targets different from CB$_1$ and CB$_2$ such as orphan G-protein-coupled receptors (GPR55), peroxisome proliferator-activated nuclear receptors (PPARs) and transient
receptor potential (TRP) channels. Moreover, several metabolic enzymes contributed to biosynthesis or inactivation of the main eCBs. In particular, N-ArPE might release AEA in one step by NAPE-PLD action or multiple steps that involve: 1) \(\alpha,\beta\)-hydrolase-4 (ABHD4) followed by glycerophosphodiester phosphodiesterase 1 GDE1; 2) soluble phospholipase A\(_2\) (sPLA\(_2\)) followed by lysophospholipase D (lyso-PLD); 3) phospholipase C (PLC) enzymes followed by PTPN22 phosphatase. Again, eCB degradative pathways are not limited to the action of FAAH or MAGL but other enzymes such as \(\alpha,\beta\)-hydrolase-6 (ABHD6) and -12 (ABHD12) are able to hydrolyze 2-AG as well as lipoxygenases and cyclooxygenase-2 might oxidize eCBs to produce several potential novel lipid mediators [3,7]. On a final note, except for THC and \(\Delta^9\)-tetrahydrocannabivarin (THCV), other pharmacologically active phytocannabinoids do not bind to CB receptors but modulate eCB metabolism and/or activate eCB off-target receptors [3,5,7]. The eCB system signaling as well as synthetic cannabinoids and phytocannabinoids represent an important field of research in order to design and develop novel therapeutic agents for symptom relief or control of disease progression in several human diseases. In the next sections, we will collect and discuss data concerning the therapeutic value of compounds that acting on the eCB system might contribute to counteract or slow down motor disease progression. The major mechanisms involving protection of nigrostriatal neurons and recruitment of anti-inflammatory responses (microglial toxicity) in PD and HD will be scrutinized and reported.

2. Parkinson’s disease
Caudate-putamen, globus pallidus (GP), subthalamic nucleus (STN) and substantia nigra (SN) form the BG. The BG are a highly interconnected set of nuclei responsible for motor skill and the correct and balanced selection of appropriate movements. The PD pathogenesis is characterized by the progressive loss of DA neurons in the SN pars compacta (SNpc) and neurodegeneration of the DA innervation of the dorsal striatum (i.e., DA nigrostriatal system). In PD is also recognizable the deposition of \(\alpha\)-synuclein aggregates in surviving nigral neurons as well as in other brain regions. Moreover, there is also evidence of neuroinflammatory processes such as microglial cell activation and production of proinflammatory mediators and T cell infiltrations [8]. However, despite the severe impact of neuroinflammation to PD pathogenesis there is no consensus about the underlying mechanisms responsible of inflammatory responses. Accordingly, there are no disease-modifying therapies available and currently approved drugs can only improve PD symptomatology but also elicit motor complications after long-term
treatment. The existing therapies are based on the idea of DA replacement and restoring of DA signaling such as 3,4-dihydroxyphenyl-l-alanine (L-DOPA), DA reuptake inhibitors (e.g., amantadine) and DA agonists (e.g., ropinirole, pramipexole) [9]. The serious consequences of DA loss for the selection-execution of movements and accurate motor skills uncover the key importance played by DA in BG function. The BG network itself can be conceptualized as a DA-dependent system consisting of two dominant pathways: the direct one associated to the D1-like DA receptors, dynorphin-, and substantia P-expressing neurons, and the indirect pathway predominantly expressing encephalin and D2-like DA receptors [10]. The large part (90-95%) of striatal neurons are the GABAergic medium spiny neurons (MSNs) that link the cortical input and the striatum to the different output nuclei (Figure 2). The tight functional interaction between DA signaling and eCBs at BG level is epitomized by the effects induced by the alteration of eCB-mediated action on motor activity and by the fact that these effects largely depend on the DAergic system. The MSNs project to SN pars reticulata (SNpr) and the internal segment of GP (GPi) and originate the striatonigral direct pathway whereas the striatopallidal indirect pathway projects to the SNpr via the GP pars externa (GPe) and the STN [11]. In this regard, the MSN can be viewed as a central gateway that integrates information incoming from different cortical regions and mediates changes in synaptic strength in striatal circuits to shape adaptive behavioral responses. The execution of movements is the result of the fine-tuned balance between the D1 receptor-dependent facilitatory signaling and activation of motor programs through the direct striatonigral pathway and the D2 receptor-dependent inhibition of the indirect striatopallidal pathways (Figure 2).

2.1 PD, CB1 distribution and eCB-dependent plasticity

mRNA expression of CB1 receptors are maximally present at BG level [12]. The localization of CB1 receptors on presynaptic axon terminals of glutamatergic corticostriatal projecting neurons represents a key factor in the fundamental contribution of the eCB system to different forms of striatal plasticity. CB1 receptors are also densely located on presynaptic terminals of GABAergic MSNs projecting to SNpr [13]. CB1 receptors have been detected both in direct striatonigral and D1-expressing neurons and in striatopallidal and D2-expressing neurons [12]. Also other efferent striatal outputs such as GP in humans, the entopeduncular nucleus in rodents, and the GABAergic projections from the GP to the STN contain high level of CB1 receptors [13].
The DA transmission controls the plasticity of glutamatergic synapses at dorsal striatal level, and the long-term depression (LTD) at corticostriatal synapses is a well-known form of non-NMDA and activity-dependent plasticity. Notably, this form of plasticity is eCB-mediated and requires the stimulation of D2 receptors as demonstrated by the potentiation of eCB signaling and LTD enhancement upon D2 receptor activation [14,15].

The progressive loss of DAergic neurons and DA innervation of striatal circuits severely undermine corticostriatal plasticity, and in particular D2 receptor-dependent eCB-induced LTD. The impairment of corticostriatal eCB-induced LTD is responsible for the development of cardinal symptoms in PD such as tremor and bradykinesia and also for the appearance of detrimental side effects such as L-DOPA-induced dyskinesia [14,16]. From here, it emerges that striatal eCB-LTD represents a key target for novel therapeutics options in PD (Figure 2).

2.2 The eCB signaling system: control of motor behavior and neuroinflammation in PD

CB1 receptor binding is increased in PD patients and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated marmosets at caudate-putamen level [17] while a decrease in CB1 receptor availability has been observed in the SN of PD patients [18]. The eCB system undergoes a drastic remodeling during the course of PD pathogenesis. The disease modifies not only receptors but also levels of eCBs. AEA levels were found considerably amplified in cerebrospinal fluid of PD patients [19] and L-DOPA or DA receptor agonist treatment was shown to restore back AEA levels to control subjects [20]. Nevertheless, AEA levels do not change according to disease development, stages and severity, leading to suggest that these alterations might be considered as adaptive changes secondary to DA depletion [21]. Experimental reserpine- or 6-hydroxy(OH)DA-induced DA depletion abolish LTD in indirect pathway MSNs and the treatment with the FAAH inhibitor, URB597, rescues the eCB-induced LTD and ameliorate Parkinsonian motor deficits (catalepsy, motor hypoactivity) but only when co-administered with the D2 receptor agonist quinpirole [14]. This study further corroborates the notion that eCBs exert an inhibitory control on movement and motor execution and these effects depend on DAergic transmission. Systemic AEA and THC administration or synthetic CB agonists (e.g., WIN 55,212-2 or CP 55,940) reduce locomotor activity both in intact and in DA-depleted animals [22]. Since there are no CB1 receptors on DAergic neurons, the effects on DAergic transmission are indirectly mediated by CB1-containing GABAergic and glutamatergic neurons. This may help to understand why the eCB system results overactivated in PD as
consequence of the loss of DAergic innervation and facilitation of DA-evoked motor behavior [18,23].

In the context of the interaction between microglial cells, neurons and astrocytes there is the possibility to investigate the role of CB$_2$-mediated signaling in PD-associated neuroinflammatory responses. Remarkably, CB$_2$ receptors are densely expressed in the brain in the activated microglia while their expression is low in microglia quiescent state [24]. Although controversial for a long time, several recent evidence support the concept of CB$_2$ receptors neural expression in prefrontal cortex, hippocampus, SN and in GP [24]. CB$_2$ receptors appeared involved in the degeneration of nigrostriatal DAergic neurons as for the increase of CB$_2$ receptors at the level of the microglial activation recruited by MPTP-induced neural lesion [25] (Table 1). This study further shows that administration of CB$_1$/CB$_2$ agonist, WIN 55,212-2, or selective CB$_2$ receptor agonist, JWH015, reduced microglial activation and infiltration [25].

In different models of PD, the unilateral intra-striatal infusion of either 6-OHDA or the bacterial endotoxin lipopolysaccharide (LPS) produced an increase of CB$_2$ receptor gene expression and, for LPS alone, also the increase of AEA and 2-AG levels [26]. This study reported a correlation between CB$_2$ receptor overexpression and increased microglial activation, thus suggesting microglia as possible source for the increase in CB$_2$ receptor expression and CB$_2$ receptors as potential targets against PD-associated neuroinflammation. An increase of CB$_2$ receptor expression was also found earlier in the LPS-based inflammation model of PD and a neuroprotective effects after administration of the selective CB$_2$ receptor agonist HU-308 [27].

Recently, the same group [28] identified the presence of CB$_2$ receptors in nigrostriatal neurons of the human SN of PD patients that resulted expressed at lower level than control subjects. Notably, a later study [29] has found an upregulation of CB$_2$ receptor in glial cells in the SN of PD patients together with a parallel increase of activated microglia and infiltrated macrophages. This study also reveals that the pharmacological activation of CB$_2$ receptors via the administration of HU-308 counteracted LPS-induced proinflammatory responses in mice (i.e., elevation of striatal CD68 immunofluorescence and inducible nitric oxide synthase (iNOS) gene overexpression). The administration of HU-308 was also shown to be partially effective against 6-OHDA-induced DA depletion whereas the use of selective and non-selective CB$_1$ receptor agonists failed to confer protection [30] (Table 1).

2.3 The therapeutic potential of eCB-based agents in PD: to boost or to shrink?
In animal models of PD the activity of the eCB system appear enhanced as a result of the amplification of CB₁ and CB₂ mRNA levels and decreased FAAH activity [30-32]. The key objective of PD-like animal models is to improve the motor impairment evoked by the experimental depletion of DAergic source to BG (Table 1). The administration of CB₁ receptor agonists produces inhibition of both motor behavior and DA release in the BG, thus revealing its inadequacy in counteracting the motor deficits in PD and also revealing the potential exacerbation of motor symptoms as for the induction of bradykinesia [33]. Nevertheless, the stimulation of CB₁ receptors can disclose its potential as option to reduce the impact of the disabling involuntary movements induced by protracted treatment with L-DOPA. In a recent study [34], L-DOPA-induced dyskinetic movements (LIDs) were reduced by subchronic administration of WIN 55,212-2 in rats unilaterally lesioned via 6-OHDA in the medial forebrain bundle. The stimulation of CB₁ receptors can provide an anti-excitotoxic response and a neuroprotective action via the reduction of glutamate release [36]. The overactivity of glutamatergic input through the corticostriatal pathway is believed to underlie LIDs, and reduction of glutamate release by CB₁ receptor stimulation might therefore be used to reduce the incidence of LIDs. Moreover, the use of CB₁ receptor agonists against LIDs might also be supported by the decrease of GPe GABAergic output induced by the stimulation of CB₁ receptors located on the presynaptic terminals of the indirect striatopallidal pathway (see figure 2). However, at the highest dose tested, the preferential CB₁ receptor agonist HU-210 has shown only partial efficacy towards L-DOPA-induced abnormal involuntary movements (AIMs) and also elicited unwanted motor suppressant effects [37]. The anti-excitotoxic response is an important consequence of CB₁ receptors stimulation that has been described also for the decrease of glutamate release from STN-nigral neurons thus corroborating the idea that CB₁ receptor agonists might have a therapeutic value in alleviating PD-associated tremors [38]. Interestingly, the stimulation of CB₁ receptors and the increase of AEA availability via FAAH inhibition do not show the same anti-dyskinetic potential. While WIN 55,212-2 administration attenuated L-DOPA-induced abnormal AIMs, FAAH inhibition was ineffective against AIMs except when co-administered with the TRP vanilloid (TRPV1) antagonist capsazepine [39]. The latter results are in agreement with the hypothesis that the hypokinetic effects evoked by AEA might be attributable to the involvement of TRPV1-mediated transmission and, in particular, that the increase of AEA levels induce a decrease of DA release from nigrostriatal terminals [40].
On the other hand, blockade of CB\textsubscript{1} receptors has been reported to improve spontaneous motor activity after severe nigral DAergic degeneration in rats and therefore after the effects of CB\textsubscript{1} receptor antagonism, via SR 141716A, on striatonigral D1-mediated activity are reduced or suppressed [41]. With regard to the beneficial effects of CB\textsubscript{1} receptor blockade in late-stages of PD, the lack of CB\textsubscript{1} receptor expression in SNpc might account for the overactivity of eCB system and the upregulation of CB	extsubscript{1}–mediated activity observed in PD. From this view the clinical use of CB\textsubscript{1} receptor antagonists appears to provide a higher therapeutical potential that is been also associated to the increase of glutamate release induced by SR 141716A [42].

Moreover, there is evidence of antagonistic relationship between eCB-mediated signaling and D1- and D2-dependent motor behavior. The potentiation of eCB signaling by the inhibition of AEA transport abolishes D1- and D2-dependent grooming and oral stereotypies, respectively [12]. The contralateral turning induced by intra-striatal unilateral D1 receptor stimulation is potentiated by CB\textsubscript{1} receptor blockade, thus demonstrating the negative modulation exerted by CB\textsubscript{1} receptors on D1-mediated neurotransmission [12].

In another study, SR 141716A administration improved hypokinesia in intracerebroventricular 6-OHDA lesioned rats [43]. Thus, despite the moderate degree of DA loss obtained in a model of bilateral DAergic lesion, the blockade of CB\textsubscript{1} receptors induced positive effects on bradykinetic-like symptoms [43]. According to the enhancement of D2-dependent motor activity induced by SR 141716A administration, these results corroborate the idea that inhibition of CB\textsubscript{1} receptor-mediated signaling might occlude the eCB-induced inhibition of DAergic receptors. The efficacy of SR 141716A administration in improving forepaw stepping in rats with unilateral 6-OHDA-lesioned was demonstrated both alone and in concomitant administration with low dosage L-DOPA [44]. Nevertheless, it should be mentioned that SR 141716A administration failed to improve Parkinsonian-like symptoms in MPTP-treated in primates [34]. Mixed results were obtained in MPTP-treated rhesus monkeys were the selective CB\textsubscript{1} antagonist CE-178,253 was ineffective against motor disabilities except when co-administered with subthreshold doses of L-DOPA, thus enhancing the anti-Parkinsonian effects of L-DOPA treatment [45].

The block of CB\textsubscript{1}-mediated signaling may reveal its potential as strategy to reduce LIDs [46]. As shown in MPTP-treated marmosets, SR 141716A administration can improve motor function and reduce L-DOPA-induced dyskinesia [46]. Similar findings were described later in the 6-OHDA...
rat model of PD in which the co-administration of SR 141716A and L-DOPA reduced the AIMs elicited by repeated L-DOPA treatment also exerting some anti-degenerative effects in terms of preservation of DAergic nigral cells [47]. This study provides an interesting therapeutic perspective in which CB_1 receptor blockade parallels, and not follows, L-DOPA treatment and therefore might prevent the development of the AIMs.

With regard to the neuroprotective potential provided by CB_1 receptor modulation there is also evidence that CB_1 receptor stimulation can protect against MPTP-induced DAergic neuronal loss by the way of microglial activation [48] (Table 1). Nevertheless, the increase of CB_1-mediated signaling might aggravate some Parkinsonian symptoms such as bradykinesia. Moreover, an approach based on CB_1-receptor appears irreconcilable with the progressive loss of CB_1 receptors that is observed in neurodegenerative diseases. For this reason, a neuroprotective eCB-based approach would rely on other non-mutually exclusive targets as for the particular role played by CB_2 receptors in neuroinflammation.

### 2.4 Targeting eCB signaling in PD patients

Clinical studies/trials have been extensively reviewed by Kluger and co-authors [49]. Briefly, these studies described that PD patients who made use of cannabis or received nabilone (i.e., a THC mimetic) reported an improvement of motor impairment and in particular of bradykinesia, tremor and L-DOPA-induced dyskinesia. Moreover, there is evidence for possible beneficial effects of eCB system stimulation and decrease of PD-associated comorbidities such as psychosis and REM sleep behavior disorder. However, another trial that implemented a four-week oral cannabis administration in PD patients failed to show any significant anti-Parkinsonian activity. Although with a limited sample size, also a case study in which patients smoked marijuana at different THC concentrations did not report improvement of tremor symptoms. In a randomized placebo-controlled study, the administration of SR141716A was ineffective against motor symptoms and also LIDs [49].

### 3. Huntington disease

Huntington disease (HD) is a neurodegenerative genetic disorder caused by a polyglutamine expansion mutation (a CAG trinucleotide expansion) in exon 1 of the IT15 gene coding for huntingtin protein (Htt) on chromosome 4 [50]. The most characteristic symptoms of disease are
abnormal involuntary movements called chorea, which are produced by neuronal dysfunction in the striatum, and dementia caused by neuronal decline in the cortical structures. Moreover, multiple molecular and cellular events including aggregation of mutated Htt, transcriptional dysregulation, altered energy metabolism, excitotoxicity, impaired axonal transport and altered synaptic transmission contributed to neuronal dysfunction and death [50]. Most HD patients carry CAG repeats in the range of 38–55 and develop neurological symptoms in mid-life, larger repeats (>60Q) can cause juvenile onset HD [50]. Unfortunately, HD is a disease with no cure and Tetrabenazine is the only pharmacological treatment approved by the Food and Drug Administration against chorea associated with HD.

3.1 The link between HD and CB$_1$ receptor-mediated protective action

One of the earliest changes observed in HD patients and animal models of HD is transcriptional dysregulation of a subset of genes including CB$_1$ receptors. The CB$_1$ is high expressed in the brain areas that control motor and social behaviors as well as learning and memory function impaired in HD [13]. CB$_1$ receptors are significantly reduced in MSN projections of the caudate-putamen [51-53] and is thought to participate in HD pathogenesis. The downregulation of CB$_1$, observed in post-mortem tissue of HD patients and in most mouse models of HD, including R6/2, R6/1, YAC128 and HdhQ150 mice [52,54-56], seems to occur at early stages of the disease and prior the onset of choreic symptoms and neuronal death. Moreover, CB$_1$ receptor genetic ablation in mice deteriorated HD symptoms and pathology, while treatment with THC, or WIN 55,212-2 delayed the onset of motor and neurochemical alterations [36,57-59] (Table 1). A variant of the CB$_1$ gene (CNR1 rs4707436) that is related with lower levels of CB$_1$ has been associated with age at onset in HD patients [60]. Further, mutant Htt affects CB$_1$ promoter activity [59] through repressor element 1 silencing transcription factor, REST, which is implicated in the pathogenesis of HD [61,62].

Recently, the development of conditional mutant mice lacking CB$_1$ in glutamatergic excitatory neurons or GABAergic inhibitory neurons has helped to clarify the CB$_1$ receptor-dependent neuroprotective activity in HD. This neuroprotective potential appears due to a unique and well-defined population of CB$_1$ receptors located on cortical glutamatergic neurons that project to the striatum. The identification of this population of CB$_1$, preserved during HD progression, supported the development of therapeutic approaches aimed at targeting glutamatergic CB$_1$ receptors in spite of their loss [63]. In addition, eCB, synthetic cannabinoids and
phytocannabinoids exhibited biased signaling at CB1, and activation of CB1 by Gai/o- and Gβγ-selective ligands might be therapeutically beneficial in HD [64-66]. Indeed, in vitro treatment of striatal cell model of HD with AEA normalized CB1 protein levels and this effect was associated with improved cell viability, ATP production, BDNF-2 expression and inhibition of GABA release [64-66].

3.3 eCBs, CB2 receptor and the therapeutic promise in HD

However, recent evidence suggested that CB2 receptor is much more widely distributed in the CNS than originally thought, where it plays multiple and unexpected neuroprotectant roles. Compounds that selectively activate the CB2 receptor also appear to be effective in different animal models of HD. In particular, the expression of CB2 receptors is upregulated in the striatum of R6/2 mice at both pre-symptomatic and symptomatic stages and genetic ablation of CB2 receptors exacerbated disease symptomatology and neurochemical alterations in same model [67]. Moreover, CB2 receptor stimulation by the selective CB2 agonist HU-308 attenuated glial activation and protected striatal neurons from damage induced by intrastriatal injection of quinolinic acid or the mitochondrial complex II inhibitor malonate [67,68].

Besides the pivotal role of cannabinoid receptors, the participation of other elements of the eCB system in HD pathology might also be considered. In particular, FAAH activity was reported to be downregulated and eCB upregulated in peripheral lymphocytes from HD patients [69]. Striatal FAAH messenger RNA levels were upregulated in symptomatic R6/2 mice and in the caudate-putamen of patients with HD compared to control subjects [59] while Bari and co-workers [70] reported that striatal FAAH enzymatic activity was reduced in 12-week-old R6/2 mice. Again, the gene expression of MAGL remained unchanged in the striatum of R6/2 along disease progression [59] while the enzymatic activities of the main eCB biosynthetic enzymes, DAGL and NAPE-PLD, decreased in 12-week-old R6/2 mice compared to control wild-type mice [70]. Finally, a region-specific decline of eCB levels were reported in the striatum of 3-nitropropionic acid (3-NP)-lesioned rats and in symptomatic R6/2 mice [71,72].

The preclinical data reported above support the development of novel therapeutic strategies that by targeting the eCB system might contribute to new routes for drug design against HD. This might include the “direct” activation of eCB system by using specific agonists, the use of “indirect” cannabinoid receptor agonists as inhibitors of eCB inactivation or as alternative strategy the use of positive allosteric modulators.
On the other hand, the inhibitors of eCB catabolism have been tested in different animal models of HD showing controversial results and additional studies are needed to understand how elevating eCB levels affects the signs and symptoms of disease [57,72-76]. An another approach of enhancing eCB signaling is the use of positive allosteric modulators (PAMs) able to potentiate agonist binding to the CB receptors and at the same time inhibiting agonist activity in numerous functional assays [77,78]. However, further investigation is necessary to better understand the correlation between in vitro and in vivo pharmacology of PAMs [66,78]. On a final note, also the beneficial effect of the phytocannabinoids Δ9-THC and cannabidiol (CBD), alone or in combination in the form of mouth spray, Sativex®, has been investigated in several animal models of HD. Multiple mechanisms of action including CB1 or CB2 receptors, additional eCB-binding receptors like PPARs, non-eCB targets like 5HT1A receptors or even anti-oxidant properties have been supposed to be responsible of their beneficial action [79,80]. Controversial results were obtained by using phytocannabinoids [68,73,81], and improvements of hyperkinesia and behavioral alterations have been reported in clinical trials with nabilone [82]. Unfortunately, a recent phase II clinical trial with Sativex® was unsuccessful [83] probably due to short treatment period and low dose administered. More recently, cannabigerol (CBG), another phytocannabinoid with non-psychotropic profile, was investigated in both R6/2 and 3NP-lesioned mice models of HD [81]. CBG preserved striatal neurons death as well as neurological deterioration and improved motor deficits, although these effects were much more evident in 3NP-lesioned mice than in R6/2 mice. Since CBG exhibited poor affinity for CB1 and/or CB2 receptors, the mechanisms responsible for the beneficial effects of CBG in HD await to be better investigated [81].

4. Expert commentary

The eCB system is part of a wider lipid-signaling pathway capable to provide unique anti-oxidative, anti-excitotoxic, anti-inflammatory and neuroprotective properties. The expression and distribution of the major eCB system components all over the BG network and their tight interaction with DAergic, GABAergic and glutamatergic systems contribute to support the view of the therapeutic potential of eCB system in motor diseases. The protective action conferred by eCB-based drugs against age-dependent pathologies such as neuroinflammatory insult and neurodegeneration further supports the exploitation of eCB signaling in motor diseases. Ageing is associated with mitochondrial dysfunction that also occurs in occurs in PD and in HD. Since
CB₁ receptors have been found localized on brain mitochondria and contribute to reduce mitochondrial respiration and alter eCB-mediated synaptic plasticity [84,85] the eCB system can play a relevant role in mitochondrial function. Mitochondrial ROS production and in particular the oxidative stress induced by the exposure of mitochondria to paraquat were attenuated via CP55,940 and JWH-015 [86]. However, while increasing CB₁ receptor activity might impair mitochondrial function, enhancing CB₂ receptor activity exerts a neuroprotective action against inhibition of mitochondrial function as demonstrated in a rat model of HD [68]. Collectively, the possibility to limit microglial overactivation, infiltrating macrophages and confer defense against mitochondrial dysfunction given by CB₂ receptor stimulation appears the most promising strategy to fight inflammation, regulate autophagy and reduce neural death in neurotoxic models of PD and HD and potentially in multiple BG-associated motor diseases.

The examination of the key outcomes emerging from the use of cannabinoid-based drugs in BG-associated motor diseases reveals the existence of a gap between preclinical and clinical investigations. In the current scenario, preclinical studies in animal models of PD and HD are only partially convincing providing limited evidence as for the impact of cannabinoid-based drugs to attenuate bradykinesia, tremor, hypokinesia and choreic motor signs. On the other hand, clinical trials appear not to be sufficient to draw conclusive assumptions. As above mentioned, the clinical use of CB₁ receptor antagonists might reveal unexpected therapeutical chances in case of advanced stages of PD [41] or marked refractoriety to DA replacement therapy. This therapeutic opportunity appears confirmed by the predictions made possible by recent models of BG functioning as for the dynamic “centre-surround model”[87]. This model emphasizes the role of BG in facilitating motor programs but also in the inhibition of competing and interfering movements that might elicit movement disorders such as PD and HD. The “centre-surround model” is based on the idea of the selective facilitation of motor programs and concurrent “surround” inhibition of competing motor patterns. As elsewhere underlined [88], the “centre-surround model” can help to account for the failure to accomplish desired movements or inhibit undesired movements as for PD and HD, respectively. Within this context, we believe that the “centre-surround model” could be used to evaluate the predictive potential at the light of the idea of the overactivity of the CB system in movement disorders (see Figure 3 for the model adaptation to PD). Hence, CB₁ receptor blockade is expected to reduce the inhibition in striatopallidal projecting neurons and alleviate hypokinesia.
Another stimulating therapeutic field for the investigation of cannabinoid-based drugs is offered by the anti-dyskinetic potential for the clinical management of PD-associated motor symptoms [46,47]. We believe that cannabinoid-based drugs possess a great therapeutic potential that should be further explored taking into account the knowledge developed on the interaction between CB₁ receptors and other targets of the BG network that have provided robust evidence as non-DAergic substitutes to alleviate motor deficits in PD. Among non-DAergic mechanisms, the role of the adenosine A₂A receptor subtype acquires a particular relevance. Besides to D₂-A₂ₐ receptor interaction and its role in striatal plasticity, there is evidence that A₂A and CB₁ receptors co-localize in corticostral glutamatergic terminals and in dendrites of MSNs of the indirect pathway. D₂-A₂ₐ and also A₂A-CB₁ receptors can form heteromeric complexes in the striatum [89] providing the morphological basis for functional A₂A-CB₁ receptor interaction subserving the control of motor output [90]. Moreover there is evidence of physical A₂A-CB₁ receptor interaction on the same corticostral glutamatergic terminal and that A₂A receptor activation reduce the CB₁ receptor-mediated inhibition of synaptic transmission with major effects on motor coordination and PD pathophysiology [91]. Moreover, as recently reported in different PD models, the altered expression of A₂A/CB₁/D₂ heteromers induced by DA depletion can be restored by L-DOPA treatment and therefore contribute to normalize the functioning of BG network [92,93]. Although different hypotheses might be formulated to understand the influence of presynaptic A₂A receptor populations on CB₁ receptor signaling at corticostral synapses, it is also clear that the A₂A receptor is a key target for the modulation of CB₁ receptor functioning.

5. Five-year view

One of the major challenge for the use of cannabinoid-based drugs as therapeutic option for the treatment of BG-associated movement disorders is linked to the assessment of their efficacy on disease progression. Although the studies summarized in this review provided either marginal or substantial evidence to support their use in clinical practice, they have been performed in cellular or animal models whereas the few clinical trials have been focused on the alleviation of specific symptoms rather than on the control of disease progression. This could, at least in part, help to explain the controversial results obtained in clinical studies.

In our view, the approval for clinical use of Sativex and Epidiolex might facilitate in the near future the clinical utilization and development of cannabinoid-based drugs. These formulations,
or additional combination of phytocannabinoids, seem to be suitable to treat pathological situations in which the involvement of different toxic mechanisms contributes to the damage. There are nonetheless specific clues that should be followed within a short-term perspective.

1) First, it should be examined the opportunity to implement combined therapies and develop dual-acting drugs targeting the $A_{2A}$-CB$_1$ receptors taking advantage of their physical and functional interaction to rebalance the DAergic signaling and striatal plasticity.

2) Next in order, it should be further explored the impact of cannabinoid-based drugs on mitochondrial function. eCBs interfere with mitochondrial respiration by receptor- and nonreceptor-mediated mechanisms [94] and consequently affect energy homeostasis and metabolic-associated functions. Remarkably, overactivation and/or alteration of eCB system does not occur only in motor diseases but also in other neurodegenerative conditions. From this point of view, the use of CB$_1$ receptor antagonist/inverse agonists might offer new elements of analysis and investigation along with the neuroprotective effects of CB$_2$ receptor stimulation on mitochondrial function.

3) Other targets of eCBs and/or related compounds such as TRP channels and PPARs should be also carefully considered. For instance, other $N$-acyylethanolamines (e.g., oleoylethanolamide and palmitoylethanolamide) are endogenous activators of PPARs and hold a neuroprotective and/or anti-excitoxic potential. Moreover, it should be further investigated the role played by the different members of TRP channels (e.g. vanilloid-, melastatin- and ankirin-type), their activation by exogenous or endogenous cannabinoid-related compounds as well as their potential synergic or antagonistic effects in BG.

4) Finally, the role of eCB system in the regulation of autophagy machinery represents a novel and promising field of investigation. eCBs have been shown to induce autophagy in several cancer cell lines, thus contributing to cytoprotection. Considering the key role of oxidative stress and autophagy dysregulation in PD and HD there is a solid rationale to solicit future investigations on the activity of cannabinoid-based drugs in autophagy function and rebalance of cellular homeostasis.

6. Key issues

- The existence of a “bright” side of psychoactive substances is corroborated by the therapeutic use of cannabinoid-based drugs.
- eCBs and cannabinoid-based drugs can “tune up” brain locomotor circuits and play a key role in BG neural plasticity.
- eCB system shapes information processing within the BG network and participate to the function and physiology of BG.
- Time- and space-selective alterations of eCB system are linked to the onset and progression of several BG-associated diseases.
- eCBs and cannabinoid-based drugs are one of the first lines of investigations to treat BG-associated motor diseases such as PD and HD.
- The widespread diffusion of eCB targets within the different excitatory and inhibitory nuclei of BG might account for the disappointing and often inconsistent results obtained by the use of selective cannabinoid-based “magic” drug bullets.
- The great potential provided by CB₂ receptors in terms of defense against neuroinflammation and mitochondrial dysfunction is another frontier for development of cannabinoid-based drugs.
- The exploration of the potential therapeutic provided by co-localization of CB₁ receptors with other family of receptors (e.g., A₂A, TRPs and PPARs) involved in BG-associated motor diseases offer novel opportunities in clinical trials.

Funding
This work was partially supported by Ministero dell’Istruzione, dell’Università e della Ricerca (MIUR) PRIN 2009 to RC and 2010 to TB and FIRB-Merit (RBNE08HWLZ-006).

Declaration of Interest
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Legend to figures and tables
Figure 1
Schematic representation of the eCB system and the interactions with some phytocannabinoids. N-acyl-phosphatidylethanolamine-selective phospholipase D, NAPE-PLD; 2-arachidonoyl-glycerol, 2-AG; N-arachidonoyl-ethanolamine, AEA; cannabidiol, CBD; cannabinoid receptor type-1, CB₁; cannabinoid receptor type-2, CB₂; cyclooxygenase-2, COX-2; diacylglycerol lipases, DAGL; fatty acid amide hydrolase, FAAH; glycerophosphodiester phosphodiesterase 1, GDE₁;
G-protein-coupled receptors 55, GPR55; α,β–hydrolase domain containing 4, ABHD4; α,β–hydrolase domain containing 6, ABHD6; α,β–hydrolase domain containing 12, ABHD12; lipoxygenase, LOX; lysophospholipase D, lyso-PLD; monoacylglycerol lipase, MAGL; peroxisome proliferator-activated nuclear receptors, PPARs; phospholipase C, PLC; protein tyrosine phosphatase non-receptor type 22, PTPN22; soluble phospholipase A₂, sPLA₂; Δ⁹-tetrahydrocannabinol, THC; Δ⁹-tetrahydrocannabinvarin, THCV; transient receptor potential (TRP) channels.
Figure 2
Schematic model of direct and indirect pathways of BG and distribution of CB₁ receptors including their relationship with DA D2 and adenosine A₂A receptors. The striatum is the main input of BG and the output nuclei of BG are the GPe and GPi/SNr as striatonigral D1 receptor-expressing direct pathway and striatopallidal D2 receptor-expressing indirect pathway, respectively. The GABAergic projections of D1-mediated direct pathway inhibit GPi/SNr cells and stimulate motor behavior, whereas the D2-mediated indirect pathway inhibit the GPe, disinhibit the subthalamic nucleus and stimulate/excite the GPi/SNr. Arrow-ending solid lines are glutamatergic excitatory output, dotted lines are GABAergic inhibitory output and solid circle lines depict DAergic pathway. Adenosine A₂A receptor, A₂A; cannabinoid receptor type-1, CB₁; dopamine D1 receptor, D1; dopamine D2 receptor, D2; globus pallidus pars externa, GPe; globus pallidus pars interna, GPi; glutamate, Glu; medium spiny neurons, MSN; substantia nigra pars compacta, SNpc; substantia nigra pars reticulata; subthalamic nucleus, STN.
Figure 3
Schematic diagram of the dynamic “centre-surround model” (adapted from [88]). According to its early formulation [87], the model attempts to explain the role of BG in the execution of voluntary movements that include the projection between cortex and STN (i.e., hyperdirect pathway) and the widespread fibers connecting the STN to the GPi/SNpr of the direct pathway. Here, to reduce the complexity, the indirect pathway is omitted. A) In normal conditions, inputs from the cortex to the striatum (i.e., direct pathway) or to the GPi/SNr (i.e., hyperdirect pathway) can induce inhibition (grey area) or excitation (white area) of the efferent stations. The dynamism of the model depends on the “corollary” signals triggered when a voluntary movement is initiated. Corollary signals are conveyed from cortex to GPi/SNr via the hyperdirect pathway contributing to inhibit the thalamic area, competing motor programs and facilitate motor execution. Other corollary signals are transmitted in parallel through the direct pathway contributing to inhibit certain neuronal populations of GPi/SNr (see the centre area) and consequently disinhibit excitatory thalamic areas (see the centre white area of the thalamus, at the bottom). B) In PD, the activity of the hyperdirect pathway is increased whereas the activity of the direct pathway is decreased. This reduction of activity is hypothesized to increase the inhibitory output from the GPi/SNr to the excitatory thalamic areas and decrease the inhibitory output to the inhibitory thalamic areas (see the peripheral grey area of the thalamus, at the bottom) leading to hypokinesia.

Arrow-ending solid lines are glutamatergic excitatory and dotted lines are GABAergic inhibitory inputs and outputs. The different thickness of excitatory solid lines or inhibitory dotted lines designate the relative degree of excitatory or inhibitory stimulation through the cortex-striatum-GPi/SNr-thalamus axis. The different number of CB1 receptors indicate the relative degree of functional activity: Cannabinoid receptor type-1, CB1; globus pallidus pars interna, GPi; substantia nigra pars reticulata, SNpr; subthalamic nucleus, STN.
<table>
<thead>
<tr>
<th>Disease</th>
<th>Target</th>
<th>Drug</th>
<th>Effect</th>
<th>Model</th>
<th>Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Parkinson’s disease</strong></td>
<td>CB₁/CB₂ Agonist</td>
<td>THC</td>
<td>Increased bradykinesia</td>
<td>MPTP-treated mice</td>
<td>[34]</td>
</tr>
<tr>
<td></td>
<td>CB₁/CB₂ Agonist</td>
<td>WIN 55,212-2</td>
<td>Reduced microglial activation</td>
<td>MPTP-treated mice</td>
<td>[25]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Neuroprotection</td>
<td>MPTP-treated mice</td>
<td>[48]</td>
</tr>
<tr>
<td></td>
<td>CB₁/Agonist</td>
<td>SR 141716A</td>
<td>Improved hypokinesia</td>
<td>6-OHDA-treated rats</td>
<td>[43]</td>
</tr>
<tr>
<td></td>
<td>CB₂ Agonist</td>
<td>JWH015</td>
<td>Reduced microglial activation</td>
<td>MPTP-treated mice</td>
<td>[25]</td>
</tr>
<tr>
<td></td>
<td>CB₂ Agonist</td>
<td>HU-308</td>
<td>Neuroprotection</td>
<td>LPS-induced inflammation</td>
<td>[27]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Neuroprotection</td>
<td>6-OHDA-treated rats</td>
<td>[30]</td>
</tr>
<tr>
<td><strong>Huntington’s disease</strong></td>
<td>CB₁/CB₂ Agonist</td>
<td>THC</td>
<td>Attenuated motor deficit</td>
<td>R6/2 mice</td>
<td>[59]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Neuroprotection</td>
<td>striatal neuroblasts</td>
<td>[59]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Neuroprotection</td>
<td>3-Nitropropionic acid induced striatal lesions</td>
<td>[58]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Neurotoxic</td>
<td>Malonate-induced toxicity in rats</td>
<td>[57]</td>
</tr>
<tr>
<td></td>
<td>CB₁/CB₂ Agonist</td>
<td>WIN 55,212-2</td>
<td>Neuroprotection</td>
<td>Quinolinic acid-induced toxicity in rats</td>
<td>[36]</td>
</tr>
<tr>
<td></td>
<td>CB₂ Agonist</td>
<td>HU-308</td>
<td>Neuroprotection</td>
<td>Quinolinic acid-induced toxicity in rats</td>
<td>[67]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Neuroprotection</td>
<td>Malonate-induced toxicity in rats</td>
<td>[68]</td>
</tr>
</tbody>
</table>
References
*-Papers of interest
**-Papers of considerable interest

1. *Mechoulam R, Parker LA, The endocannabinoid system and the brain. Annu Rev Psychol 2013;64:21-47. This recent review provide a comprehensive examination of the endocannabinoid system from the initial studies to system characterization in several diseases and brain function.
6. Di Marzo V, De Petrocellis L. Fifty years of 'cannabinoid research' and the need for a new nomenclature. in Cannabinoids (ed V. Di Marzo), 2014;John Wiley & Sons, Ltd, Chichester, UK.

14. Kreitzer AC, Malenka RC. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 2007;445:643-647. In this influential work the authors provide evidence that MSNs belonging to the striatal indirect pathway express eCB-mediated LTD and that D2 receptors are essential in this form of plasticity.


59. **Blázquez C, Chiarlone A, Sagredo O, et al. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 2011;134:119-136. This study provides multiple evidence that CB₁ receptors are involved in HD pathogenesis.


63. **Chiarlone A, Bellochio L, Blázquez C, et al. A restricted population of CB₁ cannabinoid receptors with neuroprotective activity. Proc Natl Acad Sci U S A 2014;111:8257-8262. This study provides an elegant demonstration that a subpopulation of CB₁ receptors located on glutamatergic neurons play a key role in HD etiology.


This work provides convincing evidence that CB2 receptor activation reduces microglial activation and excitotoxicity-driven neuroinflammation.


